LETTERS TO THE EDITOR

The time of blood sampling for osteocalcin determinations

Sir: We have read the interesting article by Pietschmann et al about the serum osteocalcin concentrations in patients with rheumatoid arthritis. 1 In their work there was no mention of the time at which blood samples were taken for osteocalcin determination.

Several studies have shown a circadian rhythm of serum osteocalcin in normal adults, with peak values during the night and a nadir during the morning hours.2 Therefore, in our opinion, it is osteocalcin as a marker in clinical investigations of bone metabolism it is important to mention the time at which blood was collected for its measurement. Otherwise, interpretation of results may be difficult and comparison with values obtained in other studies impossible.

J M NOLLA
A ROZADILLA
Department of Rheumatology
Hospital de Bellvitge
University of Barcelona
Spain

Correspondence to: Dr J M Nolla, C/Numancia 95-99, Eix A, 9ª, 2º 08029 Barcelona, Spain.


The time of blood sampling for osteocalcin determinations

Sir: We have read the interesting article by Pietschmann et al about the serum osteocalcin concentrations in patients with rheumatoid arthritis. In their work there was no mention of the time at which blood samples were taken for osteocalcin determination.

Several studies have shown a circadian rhythm of serum osteocalcin in normal adults, with peak values during the night and a nadir during the morning hours. Therefore, in our opinion, it is osteocalcin as a marker in clinical investigations of bone metabolism it is important to mention the time at which blood was collected for its measurement. Otherwise, interpretation of results may be difficult and comparison with values obtained in other studies impossible.

J M NOLLA
A ROZADILLA
Department of Rheumatology
Hospital de Bellvitge
University of Barcelona
Spain

Correspondence to: Dr J M Nolla, C/Numancia 95-99, Eix A, 9ª, 2º 08029 Barcelona, Spain.


Anticardiolipin antibody negative occlusive vascular retinopathy in systemic lupus erythematosus

Sir: A strong association has recently been reported between the presence of anticardiolipin antibody and occlusive vascular disease in patients with systemic lupus erythematosus (SLE). 1 2 We now wish to report a patient with SLE who developed bilateral central retinal artery occlusion and in whom anticardiolipin antibody was not detected despite several other features suggesting the presence of antiphospholipid antibodies.

The patient, a 30 year old nursing sister, was diagnosed as having SLE in 1982. She had a history of two spontaneous abortions. In January 1986 she had a 'flare' of SLE, which resolved after one month's treatment with steroids (prednisone 50 mg daily) and chloroquine (200 mg daily). The lupus remained quiescent, both clinically and serologically, for the ensuing 10 months during treatment with prednisone (10 mg alternate days) and chloroquine (200 mg daily).

In November 1986 she developed sudden complete loss of vision in the left eye. Two days later a similar visual deficit developed in the right eye. She was admitted to Kalafong Hospital 20 hours later and ophthalmoscopy disclosed a pale fundus with a bright red fovea bilaterally. The arteries were attenuated and apparently bloodless. Foci of retinal ischaemia ('soft exudates') were also described. An ophthalmologist affirmed the appearances were pathognomonic of central retinal artery occlusion. No other clinical evidence of active lupus or other predisposing factors for central retinal artery occlusion were present. Relevant investigations showed thrombocytopenia of 34x10^9/l, a prolonged activated partial thromboplastin time (APTT) of 50-76 s (control <40 s), and positive antinuclear antibody titre of 1:40. The erythrocyte sedimentation rate, and C4 antibody, serum complement, and gammaglobulin concentrations, white cell count, haemoglobin, urine analysis, and echocardiogram were all normal. She declined further hospital treatment.

In February 1987, six days after being admitted to hospital for social reasons, she developed a right hemiplegic ischaemic attack. Again there were no other clinical or laboratory features of active lupus. The APTT was now 37 s, the rapid plasma reagin test was negative, and the antinuclear antibody titre was 1:40 (undiluted). These, together with the absence of anticardiolipin antibody, were reassuring.

Three months later she was readmitted after having developed loss of consciousness abruptly five hours earlier. She was comatose with dilated pupils, which reacted sluggishly to light. She had a right hemiparesis. A computed tomographic brain scan was performed within a few hours after admission. This showed multiple areas of low attenuation in both hemispheres consistent with infarcts. The lateral ventricles were mildly dilated and several cortical sulci appeared unduly prominent (figure). The platelet count was 52x10^9/l and APTT 76 s. Anticardiolipin antibody was once more not detected and the rapid plasma reagin test was again negative. Antibodies to Ro and La were negative but antibodies to RNP and Sm were positive. She was initially anticogulated with heparin and subsequently with warfarin. Her doses of cyclophosphamide, prednisone, and aspirin were also prescribed, but her clinical state remained unchanged and she died six weeks later. Permission for necropsy was not granted.

Recurrent fetal loss, occlusive stroke, thrombocytopenia, and a prolonged APTT— all features that existed in our patient—have been associated with the presence of antiphospholipid antibodies. 3 4 The failure in this case to detect anticardiolipin antibody is therefore noteworthy. In our recent study of SLE in black South Africans clinical features were found to be little different from those described in series from other parts of the world. 5 Four of the 30 patients had a history of cerebrovascular accidents. Of these, three were tested for the presence of anticardiolipin antibody and the levels were found to be normal in each (Desseh PH, Gledhill RF, Asherson RA, unpublished). Moreover, of the 12 other patients tested, only one was found to have a raised anticardiolipin antibody level and this patient had no clinical features of the antiphospholipid syndrome. 6 It is our impression that the incidence of antiphospholipid antibodies may be significantly less in Africans with SLE. Our patient is another example of anticardiolipin antibody negativity in the presence of probable lupus anticoagulant positivity, a finding observed by other investigators. 7 8

Although occlusion of both central retinal arteries in rapid succession, such as appeared in this patient, seems an exceptional circumstance, the observation by Stafford-Brady et al that retinopathy in SLE may be a marker of poor prognosis for survival is shown only too well by our case.

P H DESSEIN* Department of Medicine University of the Witswatersrand and Johannesburg Hospital Johannesburg South Africa

R F GLEDHILL Division of Neurology Department of Medicine University of Pretoria and Kalafong Hospital Pretoria, South Africa

R A ASHERSON Lupus Anticoagulant Research Unit The Rayne Institute St Thomas’s Hospital London

*Correspondence to Dr P H Dessein, Department of Medicine, Medical School, 7 York Road, Parktown, 2193 Johannesburg, South Africa.

The time of blood sampling for osteocalcin determinations.

J M Nolla and A Rozadilla

*Ann Rheum Dis* 1990 49: 133
doi: 10.1136/ard.49.2.133-a

Updated information and services can be found at:
http://ard.bmj.com/content/49/2/133.1.citation

These include:

References

Article cited in:
http://ard.bmj.com/content/49/2/133.1.citation#related-urls

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/